The declining royalty stream and shrinking cash base ($9.2M) against a $24M market cap suggest limited time for a strategic transaction. Monitor for any announcement of a sale, merger, or asset disposition — the strategic alternatives review is the primary catalyst. Without a deal, the company faces a going-concern risk as cash burn continues.
Price Chart
Executive Summary
TherapeuticsMD reported Q2 2026 results showing declining license revenue ($869K vs $952K YoY) and net income ($164K vs $545K YoY). The company continues to evaluate strategic alternatives including a potential sale or merger, with no timetable set. Cash position is $9.2M, providing limited runway for a $24M market cap company with declining royalty income.
Key Financial Metrics
Key Facts
- Net income from continuing operations fell to $164K from $545K YoY, a 70% decline
- License revenue decreased 8.7% YoY to $869K from $952K
- Cash and cash equivalents totaled $9.2M as of June 30, 2026
- Company continues evaluating strategic alternatives including sale or merger with no timetable
- Total operating expenses increased 2.3% to $1.7M due to higher G&A and patent write-offs
Financial Impact
Net income declined ~70% YoY to $164K; license revenue down ~$83K YoY; operating expenses up $38K
Risk Factors
- No assurance of successful strategic transaction
- Declining license revenue from licensed products
- Limited cash runway ($9.2M) relative to operating expenses
- Potential Nasdaq delisting risk given micro-cap status and declining fundamentals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-087756 |
| Document: ea029897901ex99-1.htm | 0001213900-26-087756 |
| Document: 0001213900-26-087756-index-headers.html | 0001213900-26-087756 |
| Document: 0001213900-26-087756-index.html | 0001213900-26-087756 |
| Document: 0001213900-26-087756.txt | 0001213900-26-087756 |
| 8-K Data (Synthetic) | 0001213900-26-087756 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $2.08 $2.10 | ▼ −0.96% | ▼ −2.86% | $1.80 (+13.46%) |
May 12, 2026 23w ago | 8-K | $2.02 $1.82 | ▼ −9.90% | ▼ −9.29% | $1.80 (−10.89%) |
Mar 31, 2026 29w ago | 10-K/A | $2.00 $2.11 | ▼ −5.50% | ▲ +4.22% | $1.80 (+10.00%) |
Mar 30, 2026 30w ago | 8-K | $2.02 $2.10 | ▲ +3.96% | ▼ −5.46% | $1.80 (−10.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers